Full View

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

I Maldonado, M Plata, M Gonzalez… - Human Vaccines & …, 2022 - Taylor & Francis
ABSTRACT Among women aged 27–45 years, the quadrivalent human papillomavirus
(qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic …
被引用次数：15 相关文章

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years

I Maldonado, M Plata, M Gonzalez… - Human vaccines & …, 2022 - pubmed.ncbi.nlm.nih.gov
Among women aged 27-45 years, the quadrivalent human papillomavirus (qHPV;
HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the …
[HTML] nih.gov

[HTML][HTML] Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

I Maldonado, M Plata, M Gonzalez… - Human Vaccines & …, 2022 - ncbi.nlm.nih.gov
Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men
aged 27–45 years - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years.

I Maldonado, M Plata, M Gonzalez… - Human Vaccines & …, 2022 - europepmc.org
ABSTRACT Among women aged 27–45 years, the quadrivalent human papillomavirus
(qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic …

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

I Maldonado, M Plata, M Gonzalez… - Human Vaccines …, 2022 - scholar.xjtlu.edu.cn
Abstract Among women aged 27–45 years, the quadrivalent human papillomavirus (qHPV;
HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the …

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

I Maldonado, M Plata, M Gonzalez… - Human Vaccines …, 2022 - pure.johnshopkins.edu
Abstract Among women aged 27–45 years, the quadrivalent human papillomavirus (qHPV;
HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the …